Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

PURPOSE: Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as carboplatin. PATIENTS AND METHODS: This phase I trial asses...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Yap, Timothy A., O’Carrigan, Brent, Penney, Marina S., Lim, Joline S., Brown, Jessica S., de Miguel Luken, Maria J., Tunariu, Nina, Perez-Lopez, Raquel, Rodrigues, Daniel Nava, Riisnaes, Ruth, Figueiredo, Ines, Carreira, Suzanne, Hare, Brian, McDermott, Katherine, Khalique, Saira, Williamson, Chris T., Natrajan, Rachael, Pettitt, Stephen J., Lord, Christopher J., Banerji, Udai, Pollard, John, Lopez, Juanita, de Bono, Johann S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7499606/
https://ncbi.nlm.nih.gov/pubmed/32568634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02404
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados